Southpoint Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Southpoint Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-80,000	Closed	-$27.5M	–	29
2018 Q1	$27.5M	Sell	80,000 -30,000	-27%	-$10.4M	1.22%	27
2017 Q4	$41.4M	Buy	110,000 +40,000	+57%	+$16.2M	1.97%	24
2017 Q3	$31.3M	Sell	70,000 -30,000	-30%	-$14.3M	1.29%	25
2017 Q2	$49.1M	Sell	100,000 -150,000	-60%	-$65.6M	1.94%	21
2017 Q1	$96.9M	Buy	250,000 +130,000	+108%	+$48.2M	4.11%	14
2016 Q4	$44.1M	Buy	+120,000	New	+$45.6M	2.03%	21

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Southpoint Capital Advisors's REGN Position: Q2 2018 in Review

Southpoint Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2018, closing a stake of 80,000 shares — an estimated $27.5M sold.

Southpoint Capital Advisors first reported a position in REGN in Q4 2016 and held it in 6 quarters. The position peaked at $96.9M in Q1 2017. 624 funds tracked by Wall St. Rank hold REGN as of Q2 2018.

Southpoint Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Southpoint Capital Advisors sold 80,000 Regeneron Pharmaceuticals shares in Q2 2018, an estimated $27.5M.
Southpoint Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 6 quarters.
Southpoint Capital Advisors's Regeneron Pharmaceuticals position peaked at $96.9M in Q1 2017.
624 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2018.

Based on Southpoint Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.